The association between circulating MicroRNA‐150 level and cholangiocarcinoma

Salem, Perihan; Ghazala, Rasha Abdelmawla; Gendi, Ahmed Mohamed El; Emara, Doaa M.; Ahmed, Nesma Mahmoud

doi:10.1002/jcla.23397

Cited by 23 publications

(18 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While reduced levels of miR-150 were observed in individuals with CCA, another study reported an upregulation of miR-150 in patients suffering iCCA. Remarkably, the combination of reduced miR-150 and increased CA19-9 seemed to improve the accuracy of CCA diagnosis [ 58 ]. Expression of miRNAs was further investigated in bile samples and correlated with CCA occurrence; however, their prognostic value remains inconclusive [ 57 ].…”

Section: Prognostic Serum Biomarkersmentioning

confidence: 99%

Prognostic and Predictive Molecular Markers in Cholangiocarcinoma

Pavicevic

Reichelt

Uluk

et al. 2022

Cancers

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is the second most common primary liver cancer and subsumes a heterogeneous group of malignant tumors arising from the intra- or extrahepatic biliary tract epithelium. A rising mortality from CCA has been reported worldwide during the last decade, despite significant improvement of surgical and palliative treatment. Over 50% of CCAs originate from proximal extrahepatic bile ducts and constitute the most common CCA entity in the Western world. Clinicopathological characteristics such as lymph node status and poor differentiation remain the best-studied, but imperfect prognostic factors. The identification of prognostic molecular markers as an adjunct to traditional staging systems may not only facilitate the selection of patients who would benefit the most from surgical, adjuvant or palliative treatment strategies, but may also be helpful in defining the aggressiveness of the disease and identifying patients at high-risk for tumor recurrence. The purpose of this review is to provide an overview of currently known molecular prognostic and predictive markers and their role in CCA.

show abstract

Section: Prognostic Serum Biomarkersmentioning

confidence: 99%

Prognostic and Predictive Molecular Markers in Cholangiocarcinoma

Pavicevic

Reichelt

Uluk

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Nevertheless, similarly to ctDNA/cfDNA detection in plasma, the identification of miRNA should be interpreted with caution since this biomarker can also be identified in the serum of patients affected by HCC or other liver diseases[ 175 ]. Several other circulating miRNAs have shown potential as biomarkers with the ability to discriminate between CCA and other liver diseases[ 176 - 179 ]. Loosen et al [ 177 ] analyzed the concentrations of a 4 miRNAs panel (miR-122, miR-192, miR-29b and miR-155) in serum samples from 94 patients with CCA undergoing surgical resection and 40 healthy controls.…”

Section: Lb In Ccamentioning

confidence: 99%

Liquid biopsy in cholangiocarcinoma: Current status and future perspectives

Rompianesi

Martino

Gordon-Weeks

et al. 2021

WJGO

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) are a heterogeneous group of tumors in terms of aetiology, natural history, morphological subtypes, molecular alterations and management, but all sharing complex diagnosis, management, and poor prognosis. Several mutated genes and epigenetic changes have been detected in CCA, with the potential to identify diagnostic and prognostic biomarkers and therapeutic targets. Accessing tumoral components and genetic material is therefore crucial for the diagnosis, management and selection of targeted therapies; but sampling tumor tissue, when possible, is often risky and difficult to be repeated at different time points. Liquid biopsy (LB) represents a way to overcome these issues and comprises a diverse group of methodologies centering around detection of tumor biomarkers from fluid samples. Compared to the traditional tissue sampling methods LB is less invasive and can be serially repeated, allowing a real-time monitoring of the tumor genetic profile or the response to therapy. In this review, we analysis the current evidence on the possible roles of LB (circulating DNA, circulating RNA, exosomes, cytokines) in the diagnosis and management of patients affected by CCA.

show abstract

“…They are a good source for molecular markers in the blood. They are of three kinds: microvesicles, exosomes, and apoptotic bodies ( 97 , 98 ).…”

Section: Precision Medicine In Biliary Tract Cancer: Current State and Future Directionsmentioning

confidence: 99%

Biliary Tract Cancers: Treatment Updates and Future Directions in the Era of Precision Medicine and Immuno-Oncology

et al. 2021

View full text Add to dashboard Cite

The effective management of biliary tract cancers (BTCs) has been hampered by limited options for systemic therapy. In recent years, the focus on precision medicine has made technologies such as next-generation sequencing (NGS) accessible to clinicians to identify targetable mutations in BTCs in tumor tissue (primarily) as well as blood, and to treat them with targeted therapies when possible. It has also expanded our understanding of functional pathways associated with genetic alterations and opened doors for identifying novel targets for treatment. Recent advances in the precision medicine approach allowed us to identify new molecular markers in BTCs, such as epigenetic changes (methylation and histone modification) and non-DNA markers such as messenger RNA, microRNA, and long non-coding RNA. It also made detecting these markers from non-traditional sources such as blood, urine, bile, and cytology (from fine-needle aspiration and biliary brushings) possible. As these tests become more accessible, we can see the integration of different molecular markers from all available sources to aid physicians in diagnosing, assessing prognosis, predicting tumor response, and screening BTCs. Currently, there are a handful of approved targeted therapies and only one class of immunotherapy agents (immune checkpoint inhibitors or ICIs) to treat BTCs. Early success with new targets, vascular endothelial growth factor receptor (VEGFR), HER2, protein kinase receptor, and Dickkopf-1 (DKK1); new drugs for known targets, fibroblast growth factor receptors (FGFRs) such as futabatinib, derazantinib, and erdafitinib; and ICIs such as durvalumab and tremelimumab is encouraging. Novel immunotherapy agents such as bispecific antibodies (bintrafusp alfa), arginase inhibitors, vaccines, and cellular therapy (chimeric antigen receptor—T cell or CAR-T, natural killer cells, tumor-infiltrating lymphocytes) have the potential to improve outcomes of BTCs in the coming years.

show abstract

The association between circulating MicroRNA‐150 level and cholangiocarcinoma

Cited by 23 publications

References 41 publications

Prognostic and Predictive Molecular Markers in Cholangiocarcinoma

Prognostic and Predictive Molecular Markers in Cholangiocarcinoma

Liquid biopsy in cholangiocarcinoma: Current status and future perspectives

Biliary Tract Cancers: Treatment Updates and Future Directions in the Era of Precision Medicine and Immuno-Oncology

Contact Info

Product

Resources

About